Welcome to our dedicated page for Cardiol Therapeutics SEC filings (Ticker: CRDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cardiol Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cardiol Therapeutics's regulatory disclosures and financial reporting.
Cardiol Therapeutics Inc., a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026, at 9:00 a.m. EDT, with a live webcast available via its investor website.
The company highlights its lead small-molecule candidate CardiolRx™, which targets inflammasome pathway activation and is being evaluated in the MAVERIC Program for recurrent pericarditis, including a completed Phase II MAvERIC-Pilot study and an ongoing pivotal Phase III MAVERIC trial, and in the completed Phase II ARCHER study in acute myocarditis. Cardiol also notes U.S. FDA Orphan Drug Designation for CardiolRx in pericarditis and ongoing development of CRD-38, a subcutaneous formulation aimed at inflammatory heart disease, including heart failure.
Cardiol Therapeutics Inc. reported that results from its Phase II MAvERIC study of CardiolRx™ in recurrent pericarditis have been published in the peer‑reviewed Journal of the American Heart Association. The publication appears as the pivotal Phase III MAVERIC trial evaluating CardiolRx™ in recurrent pericarditis nears full patient enrollment.
The Phase II data describe CardiolRx™ being associated with rapid, sustained reductions in pericarditis pain and inflammation, substantial reductions in pericarditis episodes per year, and a favorable safety and tolerability profile, supporting the design of the Phase III trial. Cardiol also highlights its broader pipeline, including the ARCHER program in acute myocarditis and development of CRD‑38 for inflammatory heart disease, with CardiolRx™ holding U.S. FDA Orphan Drug Designation for pericarditis.
Cardiol Therapeutics Inc. reported that it will participate in a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston on July 16, 2026, at 12:20 p.m. Eastern Time. This is an investor-focused conference appearance, not a financial results update.
The company highlights its late-stage development of CardiolRx™, a small-molecule drug targeting inflammasome pathway activation for heart conditions including recurrent pericarditis and acute myocarditis, and its pivotal Phase III MAVERIC trial. Cardiol is also developing CRD-38, a subcutaneous therapy candidate for inflammatory heart disease, including heart failure.
Cardiol Therapeutics Inc. reported the results of its 2026 Annual General Meeting of Shareholders, held virtually on June 24, 2026. Shareholders voted overwhelmingly in favour of all management resolutions.
All eight nominated directors were elected for the ensuing year, each receiving at least 96% of votes cast, and BDO Canada LLP was appointed as auditor for the next fiscal year with authority for directors to set their remuneration.
The filing also reiterates Cardiol’s focus on developing its lead small-molecule drug candidate CardiolRx™ for recurrent pericarditis and acute myocarditis, including a completed Phase II MAvERIC-Pilot study, an ongoing pivotal Phase III MAVERIC trial, and a completed Phase II ARCHER study, as well as its development of CRD-38 for inflammatory heart disease.
Cardiol Therapeutics Inc. is informing investors that its 2026 virtual Annual General Meeting of Shareholders will be webcast on June 24, 2026, at 4:30 p.m. EDT via an online portal, with participation and voting details available through the company’s investor relations website.
The company highlights its focus on anti-inflammatory and anti-fibrotic therapies for heart disease, led by its small-molecule candidate CardiolRx™, which targets inflammasome pathway activation. CardiolRx™ is being evaluated in recurrent pericarditis through the MAVERIC Program, including a completed Phase II pilot study and an ongoing pivotal Phase III trial, and has U.S. FDA Orphan Drug Designation for pericarditis. Cardiol also completed the Phase II ARCHER study in acute myocarditis and is developing CRD-38, a subcutaneous formulation intended for inflammatory heart disease, including heart failure.
Cardiol Therapeutics Inc. is convening an online-only annual general meeting of shareholders on June 24, 2026 at 4:30 p.m. EDT. Shareholders of record on May 7, 2026 can vote on electing eight directors and re‑appointing BDO Canada LLP as auditors.
The company is using notice‑and‑access to provide its circular, 2025 financial statements, and MD&A electronically, with paper copies available on request. The circular details executive and director compensation, including equity awards under Cardiol’s Omnibus Equity Incentive Plan, which allows share-based incentives tied to performance and retention.
Cardiol Therapeutics Inc. ownership update: MMCAP International Inc. SPC and MM Asset Management Inc. report shared beneficial ownership of 21,063,856 Class A Common Shares, representing 17.9% of the class as of March 31, 2026. The statement shows 15,352,317 directly owned shares plus 5,711,539 shares underlying warrants exercisable within 60 days. The filing attributes the Fund as the direct owner and the Adviser as investment manager; each Reporting Person disclaims ownership beyond the shares shown.
Cardiol Therapeutics Inc. filed a Form 6-K announcing it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ in New York on May 19, 2026 at 1:30 p.m. EDT. A live webcast and 90-day replay will be available through the Investors section of the company’s website.
The filing also highlights Cardiol as a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead drug candidate, CardiolRx™, is being studied in recurrent pericarditis in the Phase II MAvERIC-Pilot study and the ongoing pivotal Phase III MAVERIC trial, and has U.S. FDA Orphan Drug Designation for pericarditis. Cardiol has also completed the Phase II ARCHER study in acute myocarditis and is developing CRD-38, a novel subcutaneous formulation aimed at inflammatory heart disease including heart failure.
Cardiol Therapeutics Inc. reported unaudited results for the three months ended March 31, 2026, showing a net loss of $10.8 million, compared with $8.3 million a year earlier, as research and development and share-based compensation expenses increased.
Cash and cash equivalents rose to $27.7 million from $21.4 million at December 31, 2025, primarily due to a $14.85 million unit financing completed in January 2026. Management expects this cash balance to fund planned operations and milestones into Q4 2027.
The company continued advancing its cardiovascular pipeline: the pivotal Phase III MAVERIC trial in recurrent pericarditis progressed beyond 50% then 75% enrollment, ARCHER Phase II myocarditis data were published in ESC Heart Failure, and IND-enabling work for subcutaneous candidate CRD-38 is underway with a budget of about $2 million.
Cardiol Therapeutics reports that Phase II results for its lead drug candidate CardiolRx™ in recurrent pericarditis have been accepted for publication in the Journal of the American Heart Association. The study found rapid and sustained reductions in pericarditis pain and inflammation in patients with a high disease burden.
The Phase II data also showed fewer pericarditis episodes per year and a favorable safety and tolerability profile, helping shape the pivotal Phase III MAVERIC trial, which has surpassed 75% enrollment. Cardiol positions CardiolRx™ as a differentiated, non-immunosuppressive therapy targeting inflammation-driven heart diseases, supported by U.S. FDA Orphan Drug Designation for pericarditis.